Artelo Biosciences Announces Publication Of New Peer-Reviewed Research Demonstrating Protective Properties Of ART27.13 Against Muscle Degeneration Caused By Certain Cancers
Portfolio Pulse from Benzinga Newsdesk
Artelo Biosciences, Inc. (NASDAQ:ARTL) has announced new research demonstrating the protective properties of its clinical asset, ART27.13, against muscle degeneration caused by certain cancers. The research shows that ART27.13 not only increases appetite in cancer patients but also prevents muscle wasting. The company is currently evaluating ART27.13 in a Phase 2a clinical trial to determine its effect on lean body mass, weight gain, and improvement of anorexia in cancer patients.
November 09, 2023 | 2:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Artelo Biosciences' new research on ART27.13 shows potential in preventing muscle degeneration in cancer patients. The drug is currently being evaluated in a Phase 2a clinical trial.
The new research findings on ART27.13 show potential in preventing muscle degeneration in cancer patients, which could significantly improve their quality of life. This positive news could potentially increase investor confidence in Artelo Biosciences, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100